Side-by-side comparison of AI visibility scores, market position, and capabilities
Embedded lending infrastructure API for fintech companies; loan origination, underwriting, and servicing rails enabling neobanks to launch credit products competing with Unit and Synctera.
Sivo is an embedded lending infrastructure platform that enables fintech companies and financial services startups to offer credit products to their customers without building their own loan origination, underwriting, or capital infrastructure — providing the behind-the-scenes lending rails that power consumer and business lending at neobanks, earned wage access platforms, and other embedded finance products. Founded in 2021 and headquartered in the United States, Sivo targets fintech companies that want to launch credit products faster than building in-house infrastructure allows.\n\nSivo's platform provides lending API infrastructure including loan origination workflows, credit decisioning (integrating with credit bureaus and underwriting models), loan management (servicing, payments, collections), and capital deployment tools. Fintech companies connect their frontend product to Sivo's API and access the full lending stack — from application intake through credit decision to loan disbursement and ongoing servicing — without owning the capital or building the compliance infrastructure themselves.\n\nIn 2025, Sivo competes in the lending-as-a-service and embedded finance infrastructure market with Unit (banking-as-a-service with lending), Synctera, Column (banking infrastructure), and Bond (embedded banking) for fintech infrastructure market share. The embedded lending market has grown as more technology companies seek to offer financial products to their user bases. Sivo's 2025 strategy focuses on growing fintech platform customers who need credit infrastructure for earned wage access programs, BNPL alternatives, and business lending products, expanding its capital deployment capabilities, and building compliance automation for regulated lending.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.